Table 2:
Modified NIH AI and interstitial inflammation categories in LN patients with and without CKD progression.
| Categories | Total (n = 125) | Progressorsa (n = 46) | Nonprogressors (n = 79) | P-value |
|---|---|---|---|---|
| Overall NIH AI, median (IQR) | 1 (0–3) | 1 (0–4) | 1 (0–3) | .61 |
| NIH AI score ≥11, n (%) | 4 (3.2) | 1 (2.2) | 3 (3.8) | .62 |
| NIH interstitial inflammation, n (%) | .9b | |||
| None–mild | 117 (93.6) | 43 (93.5) | 74 (93.7) | |
| Moderate–severe | 8 (6.4) | 3 (6.5) | 5 (6.3) | |
| Total cortical interstitial inflammation (%) | .01b | |||
| None–mild | 97 (77.6) | 30 (65.2) | 67 (84.8) | |
| Moderate–severe | 28 (22.4) | 16 (34.8) | 12 (15.2) | |
| i-IFTA | N = 77c | n = 26 | n = 51 | .09b |
| None–mild | 34 (44.2) | 8 (30.8) | 26 (51.0) | |
| Moderate–severe | 43 (55.8) | 18 (69.2) | 25 (49.0) |
a
CKD progressors were defined as LN patients with an eGFR decrease ≥30% within 5 years after the index biopsy.
b P-values for none–mild versus moderate–severe scores between progressors and nonprogressors.
cTotal number of biopsies is smaller due to an inability to apply scores to biopsies without areas of IFTA.